Viscofan World Viscofan Group (english)

Viscofan Group


Viscofan BioEngineering

Viscofan Group releases January-September 2018 results

Main highlights of the January-September 2018 results:

>>€577.9 million in revenue. Growth of 2.6% in like-for-like terms, and a 0.5% reduction in reported revenue due to a weak set of exchange rates for the main trading currencies against the euro.

>>€153.9 million in EBITDA , down 6.6% year on year and down 2.8% in like-for-like terms against a backdrop of rising raw material and energy prices.

>>In the year to date, the Company has reported non-recurring positive income of €14.5 million in compensation for patent infringement.

>>€88.7 million in net profit, down 3.8% year-on-year.

>>Net bank debt at September 2018 stands at €50.5 million, compared with the €41.1 million reported in December 2017.

>>According to José Domingo de Ampuero y Osma, chairman of the Viscofan Group: “Market strength in the first half has slowed down in the third quarter due to the decline in emerging markets, specially China and South-East Asia. Although price increases have been successfully implemented and Viscofan keeps on gaining market share, growth expectations for the year are slightly below our initial guidance.”

All results information is available on the Investor Relations site

® Viscofan Group